Prev Close | 3.39 |
Day Low/High | 3.44 / 3.66 |
52 Wk Low/High | 3.10 / 23.04 |
Prev Close | 3.39 |
Day Low/High | 3.44 / 3.66 |
52 Wk Low/High | 3.10 / 23.04 |
Exchange | NASDAQ |
Shares Outstanding | 71.45B |
Market Cap | 242.23M |
P/E Ratio | N/A |
Div & Yield | N.A. (N.A) |
Premarket movers: Upside - +157% (reports two of its newly designed mRNA molecules can effectively destroy cancer cells grown in culture) - +13% (The Phoenix Holdings Ltd. discloses 11.60% stake; appoints Josh Tech as Chief Operations Officer, effec...
Seven investment experts participating in Moneyshow's Top Picks 2022 report share their ideas for healthy portfolio gains in 2022.
I want you to think about how quickly the long end of the U.S. Treasury curve is moving.
BLUE needs a bigger base to launch a sustained uptrend.
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
Charts are pointing the way to an upside recovery for this stock.
Diplomacy must precede presidential threats.
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
A look at possible second-quarter M&A activity in the biotech sector.
Your burning biotech questions answered in our latest mailbag.
We'll answer two of the common questions we have received so far in March.
Outside of oncology, the rare disease area is a good target for M&A in 2018.
Outside of oncology, the rare disease area is a good target for M&A in 2018.
Inertia is your biggest enemy in this market.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Monday's trending topics including bitcoin futures, Bluebird Bio and what to expect from this week's Federal Reserve meeting.
Blueprint unveiled new data from its ongoing Phase 1 study of avapritinib in advanced systemic mastocytosis at the 59th American Society of Hematology Annual Meeting.
There are some signs of selling into the strength especially in technology names.
This team is playoff-ready and built for the ages.
I've cut a few positions and haven't made any notable buys today.
Buying's good for the acquirers, which should give other companies ideas.
The key to dealing with this environment is to keep an open mind.
This biotech has done well so far this year, but now it's time to lock in some gains.
Meal worms not needed to give it strength.
Oil prices continued their upward climb Thursday, buoyed by Wednesday's landmark OPEC agreement.
Celgene's days of stellar growth will continue to stretch far into the future.
Do that if you like top ticking crowd favorites, but set a protective stop.